Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages

Shuncong Wang, Jianjun Tang, Tiantian Sun, Xiaobin Zheng, Jie Li, Hongliu Sun, Xiuling Zhou, Cuiling Zhou, Hongyu Zhang, Zhibin Cheng, Haiqing Ma, Huanhuan Sun, Shuncong Wang, Jianjun Tang, Tiantian Sun, Xiaobin Zheng, Jie Li, Hongliu Sun, Xiuling Zhou, Cuiling Zhou, Hongyu Zhang, Zhibin Cheng, Haiqing Ma, Huanhuan Sun

Abstract

Small cell lung cancer (SCLC), as a proportion, makes up only 15-17% of lung cancer cases. The development of treatments for SCLC has remained stagnant for decades, and SCLC is expected to persist as a threat to human health. To date, no publications based on large populations have been reported. We calculated survival changes in patients with SCLC during each decade between 1983 and 2012 to determine the roles of race, sex, age, and socioeconomic status (SES) on survival rates based on the Surveillance, Epidemiology, and End Results (SEER) registries. In total, 106,296 patients with SCLC were identified, with the overall incidence per 100,000 decreasing each decade from 9.6 to 7.8 to 5.8. The median survival for SCLC remained 7 months, and the 12-month relative survival rates (RSRs) remained relatively stable at 32.9%, 33.2% and 33.2% during each decade. The 5-year RSRs significantly improved from 4.9% to 5.9% to 6.4% during each decade, but remained extremely low. In addition, a narrowing of the survival gaps among SES groups and stable survival gaps between sexes were observed. Although the incidence of SCLC decreased during each decade, the overall survival remained relatively stable, highlighting the urgency of developing novel treatments and the importance of prevention and early detection.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Summary incidences of patients diagnosed as having SCLC between 1983 and 2012 at the original nine SEER sites. Incidence (a) and number (b) of SCLC cases are shown by age group (total and ages 0–34, 35–49, 50–64, 65–79, and 80+ years) and calendar period. Incidence and number of SCLC cases are grouped by sex (c,d), SES (e,f), and race (g,h), respectively.
Figure 2
Figure 2
Trends in five-year relative survival rates (a) and Kaplan-Meier survival analyses (b) for patients with SCLC at 18 SEER sites between 1983 and 2012 according to age group (total and ages 0–34, 35–49, 50–64, 65–79, and 80+ years) and calendar period.
Figure 3
Figure 3
12-month (a), 60-month (b) relative survival rates and Kaplan-Meier survival analyses from 1983 to 2012 (c) for patients with SCLC at 18 SEER sites according to sex by age group (total and ages 0–34, 35–49, 50–64, 65–79, and 80+ years).
Figure 4
Figure 4
12-month, 36-month and 60-month relative survival rates by race (a) and SES/county-level poverty rates (b) and Kaplan-Meier survival analyses according to race (c) and SES/county-level poverty rates (d) for patients with SCLC at 18 SEER sites from 1983 to 2012.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA: a cancer journal for clinicians. 2017;67:7–30.
    1. Hamilton G, Rath B. Smoking, inflammation and small cell lung cancer: recent developments. Wiener medizinische Wochenschrift. 2015;165:379–386. doi: 10.1007/s10354-015-0381-6.
    1. Kahnert, K., Kauffmann-Guerrero, D. & Huber, R. M. SCLC-State of the Art and What Does the Future Have in Store? Clinical lung cancer, 10.1016/j.cllc.2016.05.014 (2016).
    1. Dores GM, Qubaiah O, Mody A, Ghabach B, Devesa SS. A population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992–2010. BMC cancer. 2015;15:185. doi: 10.1186/s12885-015-1188-y.
    1. Paglialunga L, Salih Z, Ricciuti B, Califano R. Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? ESMO open. 2016;1:e000022. doi: 10.1136/esmoopen-2015-000022.
    1. Hensing T, Chawla A, Batra R, Salgia R. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Advances in experimental medicine and biology. 2014;799:85–117. doi: 10.1007/978-1-4614-8778-4_5.
    1. Kalemkerian GP. Advances in pharmacotherapy of small cell lung cancer. Expert opinion on pharmacotherapy. 2014;15:2385–2396. doi: 10.1517/14656566.2014.957180.
    1. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999;17:1794–1801. doi: 10.1200/JCO.1999.17.6.1794.
    1. Mamdani H, Induru R, Jalal SI. Novel therapies in small cell lung cancer. Translational lung cancer research. 2015;4:533–544.
    1. Stratigos M, Matikas A, Voutsina A, Mavroudis D, Georgoulias V. Targeting angiogenesis in small cell lung cancer. Translational lung cancer research. 2016;5:389–400. doi: 10.21037/tlcr.2016.08.04.
    1. Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nature reviews. Clinical oncology. 2015;12:511–526. doi: 10.1038/nrclinonc.2015.90.
    1. Oliver E, et al. Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax. 2001;56:785–790. doi: 10.1136/thorax.56.10.785.
    1. Corral J, et al. Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain) BMC health services research. 2015;15:70. doi: 10.1186/s12913-015-0725-3.
    1. Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years? The oncologist. 2007;12:1096–1104. doi: 10.1634/theoncologist.12-9-1096.
    1. Riess JW, Lara PN., Jr. Left behind? Drug discovery in extensive-stage small-cell lung cancer. Clinical lung cancer. 2014;15:93–95. doi: 10.1016/j.cllc.2013.12.010.
    1. Sculier JP, et al. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung cancer. 1998;19:141–151. doi: 10.1016/S0169-5002(97)00084-6.
    1. ECC 2015: First Targeted Treatment for Small Cell Lung Cancer Show Promise. .
    1. Kalemkerian GP, et al. Small cell lung cancer. Journal of the National Comprehensive Cancer Network: JNCCN. 2013;11:78–98. doi: 10.6004/jnccn.2013.0011.
    1. Kim, E. et al. Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age > 65 years) using national SEER-Medicare data. Practical radiation oncology, 10.1016/j.prro.2016.01.011 (2016).
    1. Caprario LC, Kent DM, Strauss GM. Effects of chemotherapy on survival of elderly patients with small-cell lung cancer: analysis of the SEER-medicare database. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2013;8:1272–1281. doi: 10.1097/JTO.0b013e3182a007ba.
    1. Eaton BR, et al. Effect of prophylactic cranial irradiation on survival in elderly patients with limited-stage small cell lung cancer. Cancer. 2013;119:3753–3760. doi: 10.1002/cncr.28267.
    1. Yu JB, Decker RH, Detterbeck FC, Wilson LD. Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2010;5:215–219. doi: 10.1097/JTO.0b013e3181cd3208.
    1. Lally BE, et al. Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database. Lung cancer. 2009;64:226–231. doi: 10.1016/j.lungcan.2008.08.010.
    1. Wang S, et al. Improved survival of patients with hepatocellular carcinoma and disparities by age, race, and socioeconomic status by decade, 1983–2012. Oncotarget. 2016;7:59820–59833.
    1. Sun H, Ma H, Hong G, Sun H, Wang J. Survival improvement in patients with pancreatic cancer by decade: a period analysis of the SEER database, 1981–2010. Scientific reports. 2014;4:6747. doi: 10.1038/srep06747.
    1. Ou SH, Ziogas A, Zell JA. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2009;4:37–43. doi: 10.1097/JTO.0b013e31819140fb.
    1. Hamra GB, et al. Outdoor particulate matter exposure and lung cancer: a systematic review and meta-analysis. Environ Health Perspect. 2014;122:906–911.
    1. Bray FI, Weiderpass E. Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970–2007. Int J Cancer. 2010;126:1454–1466.
    1. Thun M, Peto R, Boreham J, Lopez AD. Stages of the cigarette epidemic on entering its second century. Tob Control. 2012;21:96–101. doi: 10.1136/tobaccocontrol-2011-050294.
    1. Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2008;3:819–831. doi: 10.1097/JTO.0b013e31818020eb.
    1. Jemal A, et al. Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100:1672–1694. doi: 10.1093/jnci/djn389.
    1. Centers for Disease, C. & Prevention State-specific trends in lung cancer incidence and smoking–United States, 1999–2008. MMWR Morb Mortal Wkly Rep. 2011;60:1243–1247.
    1. Cummings KM, Proctor RN. The changing public image of smoking in the United States: 1964–2014. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2014;23:32–36. doi: 10.1158/1055-9965.EPI-13-0798.
    1. Wojtalla A, et al. Targeting the phosphoinositide 3-kinase p110-alpha isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013;19:96–105. doi: 10.1158/1078-0432.CCR-12-1138.
    1. Kim YH, et al. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene. 2006;25:130–138. doi: 10.1038/sj.onc.1209303.
    1. George J, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47–53. doi: 10.1038/nature14664.
    1. Carvajal LA, Manfredi JJ. Another fork in the road–life or death decisions by the tumour suppressor p53. EMBO reports. 2013;14:414–421. doi: 10.1038/embor.2013.25.
    1. Rudin CM, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012;18:3163–3169. doi: 10.1158/1078-0432.CCR-11-3090.
    1. Han JY, et al. A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer. Cancer. 2011;117:2178–2185. doi: 10.1002/cncr.25790.
    1. Seckl, M. J. et al. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). Journal of clinical oncology: official journal of the American Society of Clinical Oncology, JCO2016697391, 10.1200/JCO.2016.69.7391 (2017).
    1. De Ruysscher D, et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Annals of oncology: official journal of the European Society for Medical Oncology. 2016;27:1818–1828. doi: 10.1093/annonc/mdw263.
    1. Roberts HC, et al. Lung cancer screening with low-dose computed tomography: Canadian experience. Canadian Association of Radiologists journal=Journal l’Association canadienne des radiologistes. 2007;58:225–235.
    1. Eberth JM, et al. Lung cancer screening using low-dose CT: the current national landscape. Lung cancer. 2014;85:379–384. doi: 10.1016/j.lungcan.2014.07.002.
    1. Jacobs CD, Jafari ME. Early Results of Lung Cancer Screening and Radiation Dose Assessment by Low-dose CT at a Community Hospital. Clinical lung cancer. 2017
    1. Sagawa M, et al. Efficacy of low-dose computed tomography screening for lung cancer: the current state of evidence of mortality reduction. Surgery today. 2016
    1. Nadpara P, Madhavan SS, Tworek C. Guideline-concordant timely lung cancer care and prognosis among elderly patients in the United States: A population-based study. Cancer epidemiology. 2015;39:1136–1144. doi: 10.1016/j.canep.2015.06.005.
    1. Jarvis MJ, Cohen JE, Delnevo CD, Giovino GA. Dispelling myths about gender differences in smoking cessation: population data from the USA, Canada and Britain. Tob Control. 2013;22:356–360. doi: 10.1136/tobaccocontrol-2011-050279.
    1. Perkins KA. Smoking cessation in women. Special considerations. CNS Drugs. 2001;15:391–411. doi: 10.2165/00023210-200115050-00005.
    1. Jamal A, et al. Current Cigarette Smoking Among Adults - United States, 2005-2015. MMWR Morb Mortal Wkly Rep. 2016;65:1205–1211. doi: 10.15585/mmwr.mm6544a2.
    1. Blackstock AW, et al. Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006;24:407–412. doi: 10.1200/JCO.2005.02.1436.
    1. Krieger N, et al. Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter? the Public Health Disparities Geocoding Project. Am J Epidemiol. 2002;156:471–482. doi: 10.1093/aje/kwf068.
    1. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Medical care. 2002;40:IV-3–18.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera